MiNK Therapeutics(INKT) GlobeNewswire News Room·2025-03-18 11:30Core Viewpoint - MiNK Therapeutics, Inc. has made significant progress in developing allogeneic iNKT cell therapies, reporting advancements in clinical trials and financial performance for the year 2024 [1][2]. Operational Highlights - The company has advanced its mission to provide off-the-shelf iNKT cell therapies for patients with difficult-to-treat cancers and severe immune-related disorders [2]. - MiNK has strengthened its manufacturing capabilities and established strategic alliances to enhance its operational efficiency and collaboration opportunities [2]. - The company is utilizing an AI-driven drug discovery platform to create a library of phosphorylated neoantigens and proprietary TCRs, positioning itself to set new standards in oncology [2][4]. Clinical Advancements - AgenT-797 has shown enhanced immune activation and improved efficacy in combination with checkpoint inhibitors and bispecific engagers in heavily pretreated patients [7]. - Early data from a Phase 2 trial in advanced gastric cancer suggest promising activity when combining AgenT-797 with other treatments [7]. - AgenT-797 demonstrated an approximately 80% survival rate in acute respiratory distress patients compared to 10% in hospital controls [7]. - MiNK's PRAME-TCR iNKTs have shown high specificity and potent tumor-killing capabilities against resistant cancer targets [7]. - MiNK-215 has exhibited robust anti-tumor activity in metastatic colorectal cancer models [7]. Financial Highlights - MiNK ended 2024 with a cash balance of 1.7 million for Q4 and 10.8 million, or 22.5 million, or 6.3 million in 2024 from 5.8 million in private financing in 2024 and is focusing on externally funded clinical trials to advance its iNKT cell programs [7].